The FDA expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity. This makes it the first drug treatment for the disorder, which affects about 39 million adults in the United States.
The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in adults with obesity, the drugmaker Eli Lilly said Friday. The decision makes it the first drug treatment for the disorder, which affects about 39 million adults in the United States. Zepbound, which shares the same active ingredient as Lilly’s diabetes drug Mounjaro, is already approved by the FDA to treat adults who are overweight or have obesity.
or continuous positive airway pressure, is the most commonly prescribed form of PAP. Dr. Timothy Morgenthaler, a pulmonologist and sleep medicine specialist at the Mayo Clinic, noted that CPAP machines work quickly, have few health complications and are usually inexpensive.
SLEEP APNEA WEIGHT LOSS DRUG APPROVAL OBESITY GLP-1
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves weight loss drug Zepbound to treat obstructive sleep apneaThe FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Read more »
FDA approves weight loss drug Zepbound to treat obstructive sleep apneaThe FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Read more »
FDA Approves Weight-Loss Drug Zepbound for Sleep ApneaIt’s the first prescription drug to be approved to treat the condition.
Read more »
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
Read more »
FDA approves weight loss drug Zepbound for sleep apneaBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortageThe decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.
Read more »